EluSys May Launch HP System For Defense Uses Without Human Efficacy Data
Executive Summary
EluSys Therapeutics anticipates commercialization of its first product, a heteropolymer monoclonal antibody injection for the treatment of blood-borne viruses, will be accelerated by FDA's recent proposal regarding products for the management of bioterrorism.